Mirvetuximab soravtansine
| Mirvetuximab soravtansine | |
|---|---|
| Term | Mirvetuximab soravtansine |
| Short definition | Mirvetuximab soravtansine - (SEA-vehicle-TUK-sih-mab SOH-rav-TAN-seen) drug used to treat adults with folate receptor alpha-positive ovarian epithelial, fallopian tube, or primary peritoneal cancer that has not improved after treatment with platinum chemotherapy. It is used in patients whose cancer has been treated with 1 to 3 other systemic therapies. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Mirvetuximab soravtansine - (SEA-vehicle-TUK-sih-mab SOH-rav-TAN-seen) drug used to treat adults with folate receptor alpha-positive ovarian epithelial, fallopian tube, or primary peritoneal cancer that has not improved after treatment with platinum chemotherapy. It is used in patients whose cancer has been treated with 1 to 3 other systemic therapies. It is also being studied in the treatment of other types of cancer. Mirvetuximab soravtansin contains a monoclonal antibody that attaches to a protein called folate receptor alpha, which is found on some cancer cells. It also contains a cancer drug that can help kill cancer cells. Mirvetuximab soravtansine is a type of antibody-drug conjugate. Also called Elahere
External links
- Medical encyclopedia article on Mirvetuximab soravtansine
- Wikipedia's article - Mirvetuximab soravtansine
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski